Eptinezumab-Jjmr — Active Pharmaceutical Ingredient

Eptinezumab-Jjmr is an active pharmaceutical ingredient found in 1 FDA-approved drug product. Forms: INJECTABLE. Routes: INJECTION.

This content is for informational purposes only. Always consult a healthcare professional.

Eptinezumab-Jjmr (1 brand name, 1 dosage form, 1 route)

Available dosage forms: INJECTABLE.

Routes of administration: INJECTION.

Brand Names

  • VYEPTI

Indications and Usage

VYEPTI is indicated for the preventive treatment of migraine in adults.

Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients in VYEPTI. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.1)].

Adverse Reactions

The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1)]. Constipation with Serious Complications [see Warnings and Precautions (5.2)] Hypertension [see Warnings and Precautions (5.3)] Raynaud’s Phenomenon [see Warnings and Precautions (5.4)]

Mechanism of Action

Eptinezumab-jjmr is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.